Cyclophosphamide

Refractory Cancer

National Cancer Institute (NCI)Small moleculePhase 2Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 73/ 100

Competitive context

44 Active assets in the Refractory Cancer cohort.

Asset / Sponsor	Phase	Rating
Eloxatin M.D. Anderson Cancer Center	Phase 2	B
Tocilizumab University Health Network, Toronto	Phase 4	B
Irinotecan Children's Oncology Group	Phase 2	B
Epirubicin Memorial Sloan Kettering Cancer Center	Phase 2	B
Pembrolizumab GV20 Therapeutics	Phase 2	B

View all 50 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

mycosis fungoidesDormant

BBB

Indicative ·

78 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.